Zealand Strikes AI Obesity Drug Deal Worth $1.2B

Nearly $1.2 billion in milestone payments, plus tiered royalties on net sales, defined the collaboration and license agreement Zealand Pharma and Generate Biomedicines announced for protein therapeutics aimed at obesity and other metabolic diseases.

From its base in Copenhagen, Denmark, the biotechnology firm would pay Generate a $30 million upfront fee. Generate was eligible for up to $35 million in early preclinical milestone payments. Preclinical work covers the laboratory testing done before a drug is tried in people, and those payments would release as defined early research goals were met. Development milestones, regulatory milestones, and commercial milestones could follow and fill out the rest of that total. Tiered royalties on net sales would apply to future worldwide sales of any commercialized products resulting from the collaboration. The agreement covered two initial programs and held an option to add a third. Ropes & Gray LLP advised Generate. Cooley LLP advised Zealand Pharma. The upfront cash was non-dilutive—money that did not require issuing new shares.

Singh and Generate chief executive Mike Nally each issued statements in the companies’ press release.

“We are thrilled to collaborate with Generate, a leader in AI and structure-enabled drug generation. This collaboration expands our toolbox to include proteins, complementing our existing small-molecule and peptide capabilities and opening new approaches for polypharmacology for innovative therapeutics,” Singh said.

Polypharmacology means designing one medicine to act on more than one biological pathway at once. Obesity involves overlapping systems of appetite, energy use, and metabolism, and the field has been pushing past single-target drugs toward molecules that can address several at the same time. Proteins would give Zealand a modality it did not already hold beside the small molecules and peptides that had defined its work.

What the peptide house carried into that October announcement was a year already marked by sharp turns in its own stock and science.

In March 2026 the shares dropped 36 percent after weak mid-stage efficacy data on petrelintide. They dropped another 23 percent in June when further trial disclosures showed high dropout rates. Those were the two worst days for the stock since the company’s 2010 listing. Petrelintide, an amylin analogue, sat inside a Roche partnership signed the year before and worth up to $5.3 billion, with $1.65 billion paid upfront. Amylin can reduce energy intake and raise energy expenditure at once; an analogue built on it gave Zealand a route distinct from the GLP-1 receptor agonists—drugs such as semaglutide and tirzepatide that slow gastric emptying and curb appetite through the brain—which had come to dominate obesity treatment.

On October 7, six days before the Generate announcement, Zealand released mid-stage petrelintide results. Overweight and obese patients with type 2 diabetes lost up to 9.2 percent of body weight. The numbers arrived after two deep drawdowns. Zealand’s identity had been peptides. What it still did not have was a way to design the next class of molecule on its own.

Generate would lead research through lead-candidate selection on the multispecific protein therapeutics. Lead-candidate selection marks the choice of a molecule to advance out of research and into formal development. Zealand would assume clinical development from that point, take on the regulatory submissions, and run worldwide commercialization of any resulting therapeutics.

“We are excited to bring together Zealand Pharma’s deep expertise in peptide therapeutics and metabolic disease with Generate’s cutting-edge computational platform and experimental capabilities to address the continued unmet medical need for patients with cardiometabolic disease,” Nally said.

The Generate Platform integrates generative AI with high-throughput experimental validation. It proposes protein structures first, then tests large numbers of those designs in the laboratory to learn which ones actually function. The work is aimed at multispecific candidates—proteins built to act on more than one biological target. Generate is backed by Flagship Pioneering. The company listed on Nasdaq under the ticker GENB on February 27, 2026. Its IPO was priced at $16 a share. Shares fell about 21 percent on the first day of trading.

“This collaboration reflects our strategy of expanding our platform and integrating our metabolic expertise in Copenhagen with the multi-modality expertise in Cambridge to develop next-generation therapeutics for metabolic health,” Singh said.

Zealand had more than 25 years of peptide research and development behind that claim. Peptides are short chains of amino acids used as medicines that can signal the body to curb appetite or alter metabolism; they had been the company’s core focus. From that work, more than 10 company-invented drug candidates had entered clinical development. Two products had reached the market. Three candidates were in late-stage development.

The Metabolic Frontier 2030 strategy set the next horizon. It aimed to launch multiple programs by 2030 and to push the company into new modalities—proteins alongside the small-molecule and peptide capabilities it already held—without building a protein-design operation from scratch. The metabolic expertise would stay centered in Copenhagen. The multi-modality design work would come from Cambridge. How the teams would set the first targets of that work was the immediate step.

“Together, our teams will first define what a great medicine for patients looks like for each of the two initial programs, and then leverage The Generate Platform to design multispecific candidates that meet or exceed that profile,” Nally said.

Early preclinical milestones would be the first scorecard on whether the laboratory research cleared its goals. The optional third program was the watch-item under the agreement. Generate’s shares rose about 5 percent in after-hours trading following the announcement.